Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy: Embracing nuclear medicine for the benefit of personalized immunotherapy

Research output: Contribution to journalScientific review

42 Citations (Scopus)
83 Downloads (Pure)

Abstract

Molecular imaging of the immune checkpoint receptor PD-1 and its ligand PD-L1 is increasingly investigated as a strategy to guide and monitor PD-1:PD-L1-targeted immune checkpoint therapy. We provide an overview of the current state-of-the-art on PD-1- and PD-L1-specific imaging agents for quantitative, real-time assessment of PD-1:PD-L1 expression in the tumor environment and discuss their potential for clinical translation.
Original languageEnglish
Pages (from-to)3559-3570
Number of pages12
JournalTheranostics
Volume8
Issue number13
DOIs
Publication statusPublished - 7 Jun 2018

Keywords

  • Biomarker
  • Immunotherapy
  • Molecular imaging
  • PD-1:PD-L1

Fingerprint

Dive into the research topics of 'Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy: Embracing nuclear medicine for the benefit of personalized immunotherapy'. Together they form a unique fingerprint.

Cite this